# Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

> **NCT00130364** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 200 (—)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Pimecrolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00130364
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 200 (—)
- **Last updated:** 2008-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130364, "Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00130364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*